These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6473093)

  • 1. Synthetic heparin fragments: new and efficient tools for the study of heparin and its interactions.
    Petitou M
    Nouv Rev Fr Hematol (1978); 1984; 26(4):221-6. PubMed ID: 6473093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site.
    Petitou M; Casu B; Lindahl U
    Biochimie; 2003; 85(1-2):83-9. PubMed ID: 12765778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases.
    Olson ST; Chuang YJ
    Trends Cardiovasc Med; 2002 Nov; 12(8):331-8. PubMed ID: 12536119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of thrombin and plasmin to heparin and antithrombin III.
    Bauer PI; Breuer Z; Machovich R; Büki KG; Horváth I
    Acta Biochim Biophys Acad Sci Hung; 1985; 20(3-4):155-61. PubMed ID: 2944348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Natural and synthetic inhibitors of thrombin. I. Natural inhibitors].
    Kibirev VK; Gershkovich AA
    Ukr Biokhim Zh (1999); 1999; 71(1):5-15. PubMed ID: 10457984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
    Olson ST; Sheffer R; Francis AM
    Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extension and structural variability of the antithrombin-binding sequence in heparin.
    Lindahl U; Thunberg L; Bäckström G; Riesenfeld J; Nordling K; Björk I
    J Biol Chem; 1984 Oct; 259(20):12368-76. PubMed ID: 6490618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin in vertebrate species: conservation of the heparin-dependent anticoagulant mechanism.
    Jordan RE
    Arch Biochem Biophys; 1983 Dec; 227(2):587-95. PubMed ID: 6607710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin.
    Griffith MJ
    J Biol Chem; 1982 Jul; 257(13):7360-5. PubMed ID: 7085630
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental proof for the structure of a thrombin-inhibiting heparin molecule.
    Petitou M; Imberty A; Duchaussoy P; Driguez PA; Ceccato ML; Gourvenec F; Sizun P; Hérault JP; Pérez S; Herbert JM
    Chemistry; 2001; 7(4):858-73. PubMed ID: 11288878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-visiting the structure of heparin.
    Casu B; Naggi A; Torri G
    Carbohydr Res; 2015 Feb; 403():60-8. PubMed ID: 25088334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of heparin cofactor II by heparin oligosaccharides.
    Maimone MM; Tollefsen DM
    Biochem Biophys Res Commun; 1988 May; 152(3):1056-61. PubMed ID: 3377765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemically synthesized heparin-derived oligosaccharides.
    Choay J
    Ann N Y Acad Sci; 1989; 556():61-74. PubMed ID: 2660689
    [No Abstract]   [Full Text] [Related]  

  • 15. A heparin analogue with specific action on antithrombin III.
    Thomas DP; Lane DA; Michalski R; Johnson EA; Kakkar VV
    Lancet; 1977 Jan; 1(8003):120-2. PubMed ID: 64653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin.
    Lane DA; Flynn AM; Pejler G; Lindahl U; Choay J; Preissner K
    J Biol Chem; 1987 Dec; 262(34):16343-8. PubMed ID: 2445746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of thrombin activity by antithrombin and heparin.
    Olson ST; Björk I
    Semin Thromb Hemost; 1994; 20(4):373-409. PubMed ID: 7899869
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
    Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
    Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III.
    Petitou M; Duchaussoy P; Lederman I; Choay J; Jacquinet JC; Sinaÿ P; Torri G
    Carbohydr Res; 1987 Sep; 167():67-75. PubMed ID: 3690577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III.
    Petitou M; Lormeau JC; Choay J
    Semin Thromb Hemost; 1991; 17 Suppl 2():143-6. PubMed ID: 1948084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.